Damian Larkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Damian Larkin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Angus Roberts
Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
2 shared publications - Barbara Arroyo
South London & Maudsley Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Maudsley Biomed Res Ctr, London, England
2 shared publications - Dipen Patel
Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, De Crespigny Pk, London SE5 8AB, England
2 shared publications - Fiona Gaughran
King's College London
2 shared publications - Julie Williams
Centre for Implementation Science, King’s College London, London, UK
2 shared publications - Omar G. Mustafa
Department of Diabetes, King's College Hospital, and King's College 7 , London, U.K.
2 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by BMJ in BMJ Connections Mental Health
- Vol. 1 (1) , e000033
Barriers and facilitators to engagement with a mental health EHR-linked digital tool: a mixed-methods study
Objectives: Digital self-management applications linked to electronic health records (EHRs) offer scalable solutions for rising mental health needs. This study evaluates how experience changes perceptions of an EHR-linked digital self-management tool (Beth). Design: An explanatory mixed-methods study comparing clinicians and service users who have or have no experience of Beth. Group differences were analysed using non-parametric tests. Qualitative data were analysed thematically. Setting: UK NHS Mental Health trust. Participants: 32 clinicians and 31 service users. Interventions: After demonstrating the digital tool, participants completed outcome measures. Main outcome measures: Technology use questionnaires, Mobile Application Rating Scale (MARS). Results: MARS ratings reflected moderate quality. Experienced service users rated engagement lower than non-users (U=166.00, z=2.68, p=0.007). Clinicians rated Beth quality more positively than service users (U=236.00, z=−3.04, p=0.002). All non-users voiced concerns about confidentiality, whereas experienced service users thought this was less problematic and instead commented on potential care team disconnection if communication was only through the app. Despite differences, both experienced and non-users highlighted the need for improved accessibility by simplifying the format and log-in processes and suggested more advanced features to increase engagement. Both clinician groups recognised the potential to enhance self-monitoring and support for service users between appointments. Conclusions: Experience of this EHR-linked digital tool appeared to increase acceptability and confidentiality views." Addressing privacy concerns, providing clinician training, and increasing co-design features is likely to increase successful implementation. Addressing potential users concerns through active promotion should encourage daily use of an EHR-linked digital tool.
- 15 April 2026
- Published by BMJ in BMJ Connections Mental Health
- Vol. 1 (1) , e000033
Open AccessBarriers and facilitators to engagement with a mental health EHR-linked digital tool: a mixed-methods study
Objectives: Digital self-management applications linked to electronic health records (EHRs) offer scalable solutions for rising mental health needs. This study evaluates how experience changes perceptions of an EHR-linked digital self-management tool (Beth). Design: An explanatory mixed-methods study comparing clinicians and service users who have or have no experience of Beth. Group differences were analysed using non-parametric tests. Qualitative data were analysed thematically. Setting: UK NHS Mental Health trust. Participants: 32 clinicians and 31 service users. Interventions: After demonstrating the digital tool, participants completed outcome measures. Main outcome measures: Technology use questionnaires, Mobile Application Rating Scale (MARS). Results: MARS ratings reflected moderate quality. Experienced service users rated engagement lower than non-users (U=166.00, z=2.68, p=0.007). Clinicians rated Beth quality more positively than service users (U=236.00, z=−3.04, p=0.002). All non-users voiced concerns about confidentiality, whereas experienced service users thought this was less problematic and instead commented on potential care team disconnection if communication was only through the app. Despite differences, both experienced and non-users highlighted the need for improved accessibility by simplifying the format and log-in processes and suggested more advanced features to increase engagement. Both clinician groups recognised the potential to enhance self-monitoring and support for service users between appointments. Conclusions: Experience of this EHR-linked digital tool appeared to increase acceptability and confidentiality views." Addressing privacy concerns, providing clinician training, and increasing co-design features is likely to increase successful implementation. Addressing potential users concerns through active promotion should encourage daily use of an EHR-linked digital tool.
- Open Access
- 5 April 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e49548
Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial
Background: Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. Objective: We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. Methods: This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. Results: Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. Conclusions: An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. Trial Registration: ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268
- 5 April 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e49548
Open AccessImplementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial
Background: Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. Objective: We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. Methods: This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. Results: Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. Conclusions: An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. Trial Registration: ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268
- Open Access
- 2 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial (Preprint)
BACKGROUND Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. OBJECTIVE We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. METHODS This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. RESULTS Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. CONCLUSIONS An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. CLINICALTRIAL ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/49548
- 2 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial (Preprint)
BACKGROUND Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. OBJECTIVE We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. METHODS This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. RESULTS Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. CONCLUSIONS An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. CLINICALTRIAL ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/49548